GlaxoSmithKline Consumer Healthcare Ltd. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, amounted to 21.90 Indian rupees per share, compared with the S&P Capital IQ consensus estimate of 23.89 rupees per share.
EPS rose 21.5% year over year from 18.03 rupees.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 921.0 million rupees, an increase of 21.5% from 758.2 million rupees in the prior-year period.
The normalized profit margin climbed to 9.4% from 9.0% in the year-earlier period.
Total revenue rose 16.2% on an annual basis to 9.75 billion rupees from 8.39 billion rupees, and total operating expenses climbed 15.8% from the prior-year period to 8.82 billion rupees from 7.62 billion rupees.
Reported net income grew 20.9% on an annual basis to 964.1 million rupees, or 22.92 rupees per share, from 797.5 million rupees, or 18.96 rupees per share.
As of Feb. 3, US$1 was equivalent to 61.67 Indian rupees.
